SK Bio-Pharmaceuticals (SKBP) is an international research and development company specializing in the discovery of small molecule drug candidates and their development from drug target through commercialization. SKBP's singular expertise in combinatorial chemistry and functional genomics drives an accelerated discovery process that optimizes the design of new chemical entities.

SKBP's research programs focus on designing compounds to treat neurologic, psychiatric, and metabolic diseases, asthma, pain, and inflammations. Initial R&D efforts have resulted in US INDs for two novel compounds, both of which have been licensed to Johnson & Johnson.

SKBP is a wholly-owned subsidiary of SK Corporation, a globally recognized life sciences company. SKBP and its parent company are two of the 40 member companies on six continents that comprise the SK Group, the third largest conglomerate in Korea.

   
Copyright 2007 by SK Bio-Pharmaceuticals